[
  {
    "sentence": "Based on the emergence of additional substantiation from evidence-based medicine, the current treatment protocol for inoperable breast cancer is described as follows (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2A uses a blue bar to depict the temporal distribution of publications related to the applications of INPs in diagnosing and treating breast cancer.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2B provides a global overview of these studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The three clusters with the most contributions included “different electrochemical biosensors,” “cancer diagnosis,” and “accurate monitoring” (Fig. 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A timeline-based analysis was conducted to understand how these clusters were distributed across various periods (Fig. 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Keyword co-occurrence analysis revealed that the research hotspots could be divided into eight categories (Fig. 2E).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 summarizes SPIONs currently available for MRI in breast cancer.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "More importantly, compared with clinically used Gd-based small molecule contrast agents, TUG can be more engulfed by 4T1 cells, showing much enhanced T1-weighted positive MRI in both subcutaneous and orthotopic tumor models of breast cancer (the highest signal value of Magnevist = 390, whereas TUG = 430) (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the CT imaging signal of the breast tumor tissue was more than twice as strong at 3 h after injection compared with the pre-contrast image (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These characters underscore the nanohorns’ ability to persist in the tumor environment, enabling clear and detailed imaging crucial for precise tumor diagnosis (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "STBRs (signal-to-background ratios) of bMSN@T2-RGD-Acrk were nearly 2.4-fold greater than bMSN@T2-AM, suggesting that bMSN@T2-RGD-Acrk, as a targeted fluorescent nanoprobe, has significant binding and imaging capabilities for breast cancer cells, thus holding substantial value for the diagnosis and monitoring of breast cancer (Fig. 4D).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the electron microscopy results demonstrated that the nanomaterial was endocytosed by tumor, liver Kupffer cells, and spleen macrophages, indicating that it could be used for SERS imaging and removed from the body (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Although microfluidic biosensor based on INP achieved a test sensitivity of 0.01 U/mL, 0.01 U/mL, and 1 pg/mL, it strongly highlights the application value of this microfluidic chip in an early diagnosis of breast cancer (Fig. 4F).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In another study, Rajaee et al. reported the radiosensitizing ability of PEG-modified bismuth gadolinium oxide (BiGdO3-PEG NPs) in MCF-7 and 4T1 breast cancer cells (Fig. 5A) [135].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "For the first time, they evaluated the potential of KI NPs as a radiosensitizer to enhance radiotherapy in MCF-7 breast cancer cells (Fig. 5B) [144].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "To develop a novel photothermal conversion agent for the treatment of TNBC, Cheng et al. designed a novel microwave-triggered heat shock protein (HSP)-targeted gold nanosystem (cmHSP-AuNC) to improve the accumulation of gold nanomaterials by specifically targeting 4T1 cells (Fig. 6A) [161].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "For example, Ying et al. developed a novel biocompatible nanoparticle CuS@BSA-NB2 for HER2-positive breast cancer treatment (Fig. 6B) [178].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "HMSNs are used to deliver the PS and methylene blue to perform the PDT effect, and the BSA-FA structure increases the targeting ability of HMSNs (Fig. 6C) [201, 202].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Yuan et al. combined hyaluronic acid (HA) and glucose oxidase (GOX) with iridium oxide nanoparticles to create an in situ amplifier: IrO2–GOx@HA NPs (Fig. 6D) [205].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Sun et al. prepared AMF-responsive composite scaffolds (FA-Gel/FeNP) by using folic acid-modified gelatin and hybridized them with citrate-stable Fe3O4 NPs (Fe3O4-Citrate NPs) (Fig. 7A) [218].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Furthermore, this innovative DM-ACMSs system showed on–off drug release capability by remotely controlling AMF (Fig. 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Its ROS production rate constant was 1.96 × 10–1 min−1 (Fig. 8A), which is three- to eightfold higher than that of the previous studies, such as TiO2 nanospheres [229], Au–TiO2 nanosheets [230], or Au–TiO2 nanocomposites [231].",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The tumor was eradicated without recurrence in the 4T1 tumor-bearing mice (Fig. 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Li and colleagues constructed an HA-coated mesoporous silica-coated Fe3O4 nanoparticles (M-MSN/HA/DI)-based versatile nanoplatforms for the co-delivery of DOX and ICG into MDA-MB-231 breast cancer cells to perform T2 MR/FL/PA imaging and chemo/PTT capabilities (Fig. 9A) [235].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In another study, Xun et al. designed Fe3O4–Aushell Janus NPs coated with PEG (Fe3O4–Aushell–PEG160 NPs) to perform synergistic theranostics of MRI and PTT of breast cancer (Fig. 9B) [241].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Ma and colleagues constructed the multifunctional Fe3O4–Pd Janus NPs (Fe3O4–Pd JNPs) to synergistically facilitate magnetic and NIR hyperthermia, along with enhanced ROS production for breast cancer treatment (Fig. 9C) [244].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Based on the emergence of additional substantiation from evidence-based medicine, the current treatment protocol for inoperable breast cancer is described as follows (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2A uses a blue bar to depict the temporal distribution of publications related to the applications of INPs in diagnosing and treating breast cancer.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2B provides a global overview of these studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The three clusters with the most contributions included “different electrochemical biosensors,” “cancer diagnosis,” and “accurate monitoring” (Fig. 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A timeline-based analysis was conducted to understand how these clusters were distributed across various periods (Fig. 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Keyword co-occurrence analysis revealed that the research hotspots could be divided into eight categories (Fig. 2E).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 summarizes SPIONs currently available for MRI in breast cancer.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "More importantly, compared with clinically used Gd-based small molecule contrast agents, TUG can be more engulfed by 4T1 cells, showing much enhanced T1-weighted positive MRI in both subcutaneous and orthotopic tumor models of breast cancer (the highest signal value of Magnevist = 390, whereas TUG = 430) (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the CT imaging signal of the breast tumor tissue was more than twice as strong at 3 h after injection compared with the pre-contrast image (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These characters underscore the nanohorns’ ability to persist in the tumor environment, enabling clear and detailed imaging crucial for precise tumor diagnosis (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "STBRs (signal-to-background ratios) of bMSN@T2-RGD-Acrk were nearly 2.4-fold greater than bMSN@T2-AM, suggesting that bMSN@T2-RGD-Acrk, as a targeted fluorescent nanoprobe, has significant binding and imaging capabilities for breast cancer cells, thus holding substantial value for the diagnosis and monitoring of breast cancer (Fig. 4D).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the electron microscopy results demonstrated that the nanomaterial was endocytosed by tumor, liver Kupffer cells, and spleen macrophages, indicating that it could be used for SERS imaging and removed from the body (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Although microfluidic biosensor based on INP achieved a test sensitivity of 0.01 U/mL, 0.01 U/mL, and 1 pg/mL, it strongly highlights the application value of this microfluidic chip in an early diagnosis of breast cancer (Fig. 4F).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In another study, Rajaee et al. reported the radiosensitizing ability of PEG-modified bismuth gadolinium oxide (BiGdO3-PEG NPs) in MCF-7 and 4T1 breast cancer cells (Fig. 5A) [135].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "For the first time, they evaluated the potential of KI NPs as a radiosensitizer to enhance radiotherapy in MCF-7 breast cancer cells (Fig. 5B) [144].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "To develop a novel photothermal conversion agent for the treatment of TNBC, Cheng et al. designed a novel microwave-triggered heat shock protein (HSP)-targeted gold nanosystem (cmHSP-AuNC) to improve the accumulation of gold nanomaterials by specifically targeting 4T1 cells (Fig. 6A) [161].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "For example, Ying et al. developed a novel biocompatible nanoparticle CuS@BSA-NB2 for HER2-positive breast cancer treatment (Fig. 6B) [178].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "HMSNs are used to deliver the PS and methylene blue to perform the PDT effect, and the BSA-FA structure increases the targeting ability of HMSNs (Fig. 6C) [201, 202].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Yuan et al. combined hyaluronic acid (HA) and glucose oxidase (GOX) with iridium oxide nanoparticles to create an in situ amplifier: IrO2–GOx@HA NPs (Fig. 6D) [205].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Sun et al. prepared AMF-responsive composite scaffolds (FA-Gel/FeNP) by using folic acid-modified gelatin and hybridized them with citrate-stable Fe3O4 NPs (Fe3O4-Citrate NPs) (Fig. 7A) [218].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Furthermore, this innovative DM-ACMSs system showed on–off drug release capability by remotely controlling AMF (Fig. 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Its ROS production rate constant was 1.96 × 10–1 min−1 (Fig. 8A), which is three- to eightfold higher than that of the previous studies, such as TiO2 nanospheres [229], Au–TiO2 nanosheets [230], or Au–TiO2 nanocomposites [231].",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The tumor was eradicated without recurrence in the 4T1 tumor-bearing mice (Fig. 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Li and colleagues constructed an HA-coated mesoporous silica-coated Fe3O4 nanoparticles (M-MSN/HA/DI)-based versatile nanoplatforms for the co-delivery of DOX and ICG into MDA-MB-231 breast cancer cells to perform T2 MR/FL/PA imaging and chemo/PTT capabilities (Fig. 9A) [235].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In another study, Xun et al. designed Fe3O4–Aushell Janus NPs coated with PEG (Fe3O4–Aushell–PEG160 NPs) to perform synergistic theranostics of MRI and PTT of breast cancer (Fig. 9B) [241].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Ma and colleagues constructed the multifunctional Fe3O4–Pd Janus NPs (Fe3O4–Pd JNPs) to synergistically facilitate magnetic and NIR hyperthermia, along with enhanced ROS production for breast cancer treatment (Fig. 9C) [244].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Based on the emergence of additional substantiation from evidence-based medicine, the current treatment protocol for inoperable breast cancer is described as follows (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2A uses a blue bar to depict the temporal distribution of publications related to the applications of INPs in diagnosing and treating breast cancer.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2B provides a global overview of these studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The three clusters with the most contributions included “different electrochemical biosensors,” “cancer diagnosis,” and “accurate monitoring” (Fig. 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A timeline-based analysis was conducted to understand how these clusters were distributed across various periods (Fig. 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Keyword co-occurrence analysis revealed that the research hotspots could be divided into eight categories (Fig. 2E).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 summarizes SPIONs currently available for MRI in breast cancer.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "More importantly, compared with clinically used Gd-based small molecule contrast agents, TUG can be more engulfed by 4T1 cells, showing much enhanced T1-weighted positive MRI in both subcutaneous and orthotopic tumor models of breast cancer (the highest signal value of Magnevist = 390, whereas TUG = 430) (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the CT imaging signal of the breast tumor tissue was more than twice as strong at 3 h after injection compared with the pre-contrast image (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These characters underscore the nanohorns’ ability to persist in the tumor environment, enabling clear and detailed imaging crucial for precise tumor diagnosis (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "STBRs (signal-to-background ratios) of bMSN@T2-RGD-Acrk were nearly 2.4-fold greater than bMSN@T2-AM, suggesting that bMSN@T2-RGD-Acrk, as a targeted fluorescent nanoprobe, has significant binding and imaging capabilities for breast cancer cells, thus holding substantial value for the diagnosis and monitoring of breast cancer (Fig. 4D).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the electron microscopy results demonstrated that the nanomaterial was endocytosed by tumor, liver Kupffer cells, and spleen macrophages, indicating that it could be used for SERS imaging and removed from the body (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Although microfluidic biosensor based on INP achieved a test sensitivity of 0.01 U/mL, 0.01 U/mL, and 1 pg/mL, it strongly highlights the application value of this microfluidic chip in an early diagnosis of breast cancer (Fig. 4F).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In another study, Rajaee et al. reported the radiosensitizing ability of PEG-modified bismuth gadolinium oxide (BiGdO3-PEG NPs) in MCF-7 and 4T1 breast cancer cells (Fig. 5A) [135].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "For the first time, they evaluated the potential of KI NPs as a radiosensitizer to enhance radiotherapy in MCF-7 breast cancer cells (Fig. 5B) [144].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "To develop a novel photothermal conversion agent for the treatment of TNBC, Cheng et al. designed a novel microwave-triggered heat shock protein (HSP)-targeted gold nanosystem (cmHSP-AuNC) to improve the accumulation of gold nanomaterials by specifically targeting 4T1 cells (Fig. 6A) [161].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "For example, Ying et al. developed a novel biocompatible nanoparticle CuS@BSA-NB2 for HER2-positive breast cancer treatment (Fig. 6B) [178].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "HMSNs are used to deliver the PS and methylene blue to perform the PDT effect, and the BSA-FA structure increases the targeting ability of HMSNs (Fig. 6C) [201, 202].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Yuan et al. combined hyaluronic acid (HA) and glucose oxidase (GOX) with iridium oxide nanoparticles to create an in situ amplifier: IrO2–GOx@HA NPs (Fig. 6D) [205].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Sun et al. prepared AMF-responsive composite scaffolds (FA-Gel/FeNP) by using folic acid-modified gelatin and hybridized them with citrate-stable Fe3O4 NPs (Fe3O4-Citrate NPs) (Fig. 7A) [218].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Furthermore, this innovative DM-ACMSs system showed on–off drug release capability by remotely controlling AMF (Fig. 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Its ROS production rate constant was 1.96 × 10–1 min−1 (Fig. 8A), which is three- to eightfold higher than that of the previous studies, such as TiO2 nanospheres [229], Au–TiO2 nanosheets [230], or Au–TiO2 nanocomposites [231].",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The tumor was eradicated without recurrence in the 4T1 tumor-bearing mice (Fig. 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Li and colleagues constructed an HA-coated mesoporous silica-coated Fe3O4 nanoparticles (M-MSN/HA/DI)-based versatile nanoplatforms for the co-delivery of DOX and ICG into MDA-MB-231 breast cancer cells to perform T2 MR/FL/PA imaging and chemo/PTT capabilities (Fig. 9A) [235].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In another study, Xun et al. designed Fe3O4–Aushell Janus NPs coated with PEG (Fe3O4–Aushell–PEG160 NPs) to perform synergistic theranostics of MRI and PTT of breast cancer (Fig. 9B) [241].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Ma and colleagues constructed the multifunctional Fe3O4–Pd Janus NPs (Fe3O4–Pd JNPs) to synergistically facilitate magnetic and NIR hyperthermia, along with enhanced ROS production for breast cancer treatment (Fig. 9C) [244].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Based on the emergence of additional substantiation from evidence-based medicine, the current treatment protocol for inoperable breast cancer is described as follows (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2A uses a blue bar to depict the temporal distribution of publications related to the applications of INPs in diagnosing and treating breast cancer.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2B provides a global overview of these studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The three clusters with the most contributions included “different electrochemical biosensors,” “cancer diagnosis,” and “accurate monitoring” (Fig. 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A timeline-based analysis was conducted to understand how these clusters were distributed across various periods (Fig. 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Keyword co-occurrence analysis revealed that the research hotspots could be divided into eight categories (Fig. 2E).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 summarizes SPIONs currently available for MRI in breast cancer.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "More importantly, compared with clinically used Gd-based small molecule contrast agents, TUG can be more engulfed by 4T1 cells, showing much enhanced T1-weighted positive MRI in both subcutaneous and orthotopic tumor models of breast cancer (the highest signal value of Magnevist = 390, whereas TUG = 430) (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the CT imaging signal of the breast tumor tissue was more than twice as strong at 3 h after injection compared with the pre-contrast image (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These characters underscore the nanohorns’ ability to persist in the tumor environment, enabling clear and detailed imaging crucial for precise tumor diagnosis (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "STBRs (signal-to-background ratios) of bMSN@T2-RGD-Acrk were nearly 2.4-fold greater than bMSN@T2-AM, suggesting that bMSN@T2-RGD-Acrk, as a targeted fluorescent nanoprobe, has significant binding and imaging capabilities for breast cancer cells, thus holding substantial value for the diagnosis and monitoring of breast cancer (Fig. 4D).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the electron microscopy results demonstrated that the nanomaterial was endocytosed by tumor, liver Kupffer cells, and spleen macrophages, indicating that it could be used for SERS imaging and removed from the body (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Although microfluidic biosensor based on INP achieved a test sensitivity of 0.01 U/mL, 0.01 U/mL, and 1 pg/mL, it strongly highlights the application value of this microfluidic chip in an early diagnosis of breast cancer (Fig. 4F).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In another study, Rajaee et al. reported the radiosensitizing ability of PEG-modified bismuth gadolinium oxide (BiGdO3-PEG NPs) in MCF-7 and 4T1 breast cancer cells (Fig. 5A) [135].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "For the first time, they evaluated the potential of KI NPs as a radiosensitizer to enhance radiotherapy in MCF-7 breast cancer cells (Fig. 5B) [144].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "To develop a novel photothermal conversion agent for the treatment of TNBC, Cheng et al. designed a novel microwave-triggered heat shock protein (HSP)-targeted gold nanosystem (cmHSP-AuNC) to improve the accumulation of gold nanomaterials by specifically targeting 4T1 cells (Fig. 6A) [161].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "For example, Ying et al. developed a novel biocompatible nanoparticle CuS@BSA-NB2 for HER2-positive breast cancer treatment (Fig. 6B) [178].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "HMSNs are used to deliver the PS and methylene blue to perform the PDT effect, and the BSA-FA structure increases the targeting ability of HMSNs (Fig. 6C) [201, 202].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Yuan et al. combined hyaluronic acid (HA) and glucose oxidase (GOX) with iridium oxide nanoparticles to create an in situ amplifier: IrO2–GOx@HA NPs (Fig. 6D) [205].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Sun et al. prepared AMF-responsive composite scaffolds (FA-Gel/FeNP) by using folic acid-modified gelatin and hybridized them with citrate-stable Fe3O4 NPs (Fe3O4-Citrate NPs) (Fig. 7A) [218].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Furthermore, this innovative DM-ACMSs system showed on–off drug release capability by remotely controlling AMF (Fig. 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Its ROS production rate constant was 1.96 × 10–1 min−1 (Fig. 8A), which is three- to eightfold higher than that of the previous studies, such as TiO2 nanospheres [229], Au–TiO2 nanosheets [230], or Au–TiO2 nanocomposites [231].",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The tumor was eradicated without recurrence in the 4T1 tumor-bearing mice (Fig. 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Li and colleagues constructed an HA-coated mesoporous silica-coated Fe3O4 nanoparticles (M-MSN/HA/DI)-based versatile nanoplatforms for the co-delivery of DOX and ICG into MDA-MB-231 breast cancer cells to perform T2 MR/FL/PA imaging and chemo/PTT capabilities (Fig. 9A) [235].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In another study, Xun et al. designed Fe3O4–Aushell Janus NPs coated with PEG (Fe3O4–Aushell–PEG160 NPs) to perform synergistic theranostics of MRI and PTT of breast cancer (Fig. 9B) [241].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Ma and colleagues constructed the multifunctional Fe3O4–Pd Janus NPs (Fe3O4–Pd JNPs) to synergistically facilitate magnetic and NIR hyperthermia, along with enhanced ROS production for breast cancer treatment (Fig. 9C) [244].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Based on the emergence of additional substantiation from evidence-based medicine, the current treatment protocol for inoperable breast cancer is described as follows (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2A uses a blue bar to depict the temporal distribution of publications related to the applications of INPs in diagnosing and treating breast cancer.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2B provides a global overview of these studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The three clusters with the most contributions included “different electrochemical biosensors,” “cancer diagnosis,” and “accurate monitoring” (Fig. 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A timeline-based analysis was conducted to understand how these clusters were distributed across various periods (Fig. 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Keyword co-occurrence analysis revealed that the research hotspots could be divided into eight categories (Fig. 2E).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 summarizes SPIONs currently available for MRI in breast cancer.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "More importantly, compared with clinically used Gd-based small molecule contrast agents, TUG can be more engulfed by 4T1 cells, showing much enhanced T1-weighted positive MRI in both subcutaneous and orthotopic tumor models of breast cancer (the highest signal value of Magnevist = 390, whereas TUG = 430) (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the CT imaging signal of the breast tumor tissue was more than twice as strong at 3 h after injection compared with the pre-contrast image (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These characters underscore the nanohorns’ ability to persist in the tumor environment, enabling clear and detailed imaging crucial for precise tumor diagnosis (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "STBRs (signal-to-background ratios) of bMSN@T2-RGD-Acrk were nearly 2.4-fold greater than bMSN@T2-AM, suggesting that bMSN@T2-RGD-Acrk, as a targeted fluorescent nanoprobe, has significant binding and imaging capabilities for breast cancer cells, thus holding substantial value for the diagnosis and monitoring of breast cancer (Fig. 4D).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the electron microscopy results demonstrated that the nanomaterial was endocytosed by tumor, liver Kupffer cells, and spleen macrophages, indicating that it could be used for SERS imaging and removed from the body (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Although microfluidic biosensor based on INP achieved a test sensitivity of 0.01 U/mL, 0.01 U/mL, and 1 pg/mL, it strongly highlights the application value of this microfluidic chip in an early diagnosis of breast cancer (Fig. 4F).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In another study, Rajaee et al. reported the radiosensitizing ability of PEG-modified bismuth gadolinium oxide (BiGdO3-PEG NPs) in MCF-7 and 4T1 breast cancer cells (Fig. 5A) [135].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "For the first time, they evaluated the potential of KI NPs as a radiosensitizer to enhance radiotherapy in MCF-7 breast cancer cells (Fig. 5B) [144].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "To develop a novel photothermal conversion agent for the treatment of TNBC, Cheng et al. designed a novel microwave-triggered heat shock protein (HSP)-targeted gold nanosystem (cmHSP-AuNC) to improve the accumulation of gold nanomaterials by specifically targeting 4T1 cells (Fig. 6A) [161].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "For example, Ying et al. developed a novel biocompatible nanoparticle CuS@BSA-NB2 for HER2-positive breast cancer treatment (Fig. 6B) [178].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "HMSNs are used to deliver the PS and methylene blue to perform the PDT effect, and the BSA-FA structure increases the targeting ability of HMSNs (Fig. 6C) [201, 202].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Yuan et al. combined hyaluronic acid (HA) and glucose oxidase (GOX) with iridium oxide nanoparticles to create an in situ amplifier: IrO2–GOx@HA NPs (Fig. 6D) [205].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Sun et al. prepared AMF-responsive composite scaffolds (FA-Gel/FeNP) by using folic acid-modified gelatin and hybridized them with citrate-stable Fe3O4 NPs (Fe3O4-Citrate NPs) (Fig. 7A) [218].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Furthermore, this innovative DM-ACMSs system showed on–off drug release capability by remotely controlling AMF (Fig. 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Its ROS production rate constant was 1.96 × 10–1 min−1 (Fig. 8A), which is three- to eightfold higher than that of the previous studies, such as TiO2 nanospheres [229], Au–TiO2 nanosheets [230], or Au–TiO2 nanocomposites [231].",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The tumor was eradicated without recurrence in the 4T1 tumor-bearing mice (Fig. 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Li and colleagues constructed an HA-coated mesoporous silica-coated Fe3O4 nanoparticles (M-MSN/HA/DI)-based versatile nanoplatforms for the co-delivery of DOX and ICG into MDA-MB-231 breast cancer cells to perform T2 MR/FL/PA imaging and chemo/PTT capabilities (Fig. 9A) [235].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In another study, Xun et al. designed Fe3O4–Aushell Janus NPs coated with PEG (Fe3O4–Aushell–PEG160 NPs) to perform synergistic theranostics of MRI and PTT of breast cancer (Fig. 9B) [241].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Ma and colleagues constructed the multifunctional Fe3O4–Pd Janus NPs (Fe3O4–Pd JNPs) to synergistically facilitate magnetic and NIR hyperthermia, along with enhanced ROS production for breast cancer treatment (Fig. 9C) [244].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Based on the emergence of additional substantiation from evidence-based medicine, the current treatment protocol for inoperable breast cancer is described as follows (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2A uses a blue bar to depict the temporal distribution of publications related to the applications of INPs in diagnosing and treating breast cancer.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2B provides a global overview of these studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The three clusters with the most contributions included “different electrochemical biosensors,” “cancer diagnosis,” and “accurate monitoring” (Fig. 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A timeline-based analysis was conducted to understand how these clusters were distributed across various periods (Fig. 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Keyword co-occurrence analysis revealed that the research hotspots could be divided into eight categories (Fig. 2E).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 summarizes SPIONs currently available for MRI in breast cancer.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "More importantly, compared with clinically used Gd-based small molecule contrast agents, TUG can be more engulfed by 4T1 cells, showing much enhanced T1-weighted positive MRI in both subcutaneous and orthotopic tumor models of breast cancer (the highest signal value of Magnevist = 390, whereas TUG = 430) (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the CT imaging signal of the breast tumor tissue was more than twice as strong at 3 h after injection compared with the pre-contrast image (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These characters underscore the nanohorns’ ability to persist in the tumor environment, enabling clear and detailed imaging crucial for precise tumor diagnosis (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "STBRs (signal-to-background ratios) of bMSN@T2-RGD-Acrk were nearly 2.4-fold greater than bMSN@T2-AM, suggesting that bMSN@T2-RGD-Acrk, as a targeted fluorescent nanoprobe, has significant binding and imaging capabilities for breast cancer cells, thus holding substantial value for the diagnosis and monitoring of breast cancer (Fig. 4D).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the electron microscopy results demonstrated that the nanomaterial was endocytosed by tumor, liver Kupffer cells, and spleen macrophages, indicating that it could be used for SERS imaging and removed from the body (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Although microfluidic biosensor based on INP achieved a test sensitivity of 0.01 U/mL, 0.01 U/mL, and 1 pg/mL, it strongly highlights the application value of this microfluidic chip in an early diagnosis of breast cancer (Fig. 4F).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In another study, Rajaee et al. reported the radiosensitizing ability of PEG-modified bismuth gadolinium oxide (BiGdO3-PEG NPs) in MCF-7 and 4T1 breast cancer cells (Fig. 5A) [135].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "For the first time, they evaluated the potential of KI NPs as a radiosensitizer to enhance radiotherapy in MCF-7 breast cancer cells (Fig. 5B) [144].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "To develop a novel photothermal conversion agent for the treatment of TNBC, Cheng et al. designed a novel microwave-triggered heat shock protein (HSP)-targeted gold nanosystem (cmHSP-AuNC) to improve the accumulation of gold nanomaterials by specifically targeting 4T1 cells (Fig. 6A) [161].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "For example, Ying et al. developed a novel biocompatible nanoparticle CuS@BSA-NB2 for HER2-positive breast cancer treatment (Fig. 6B) [178].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "HMSNs are used to deliver the PS and methylene blue to perform the PDT effect, and the BSA-FA structure increases the targeting ability of HMSNs (Fig. 6C) [201, 202].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Yuan et al. combined hyaluronic acid (HA) and glucose oxidase (GOX) with iridium oxide nanoparticles to create an in situ amplifier: IrO2–GOx@HA NPs (Fig. 6D) [205].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Sun et al. prepared AMF-responsive composite scaffolds (FA-Gel/FeNP) by using folic acid-modified gelatin and hybridized them with citrate-stable Fe3O4 NPs (Fe3O4-Citrate NPs) (Fig. 7A) [218].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Furthermore, this innovative DM-ACMSs system showed on–off drug release capability by remotely controlling AMF (Fig. 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Its ROS production rate constant was 1.96 × 10–1 min−1 (Fig. 8A), which is three- to eightfold higher than that of the previous studies, such as TiO2 nanospheres [229], Au–TiO2 nanosheets [230], or Au–TiO2 nanocomposites [231].",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The tumor was eradicated without recurrence in the 4T1 tumor-bearing mice (Fig. 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Li and colleagues constructed an HA-coated mesoporous silica-coated Fe3O4 nanoparticles (M-MSN/HA/DI)-based versatile nanoplatforms for the co-delivery of DOX and ICG into MDA-MB-231 breast cancer cells to perform T2 MR/FL/PA imaging and chemo/PTT capabilities (Fig. 9A) [235].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In another study, Xun et al. designed Fe3O4–Aushell Janus NPs coated with PEG (Fe3O4–Aushell–PEG160 NPs) to perform synergistic theranostics of MRI and PTT of breast cancer (Fig. 9B) [241].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Ma and colleagues constructed the multifunctional Fe3O4–Pd Janus NPs (Fe3O4–Pd JNPs) to synergistically facilitate magnetic and NIR hyperthermia, along with enhanced ROS production for breast cancer treatment (Fig. 9C) [244].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Based on the emergence of additional substantiation from evidence-based medicine, the current treatment protocol for inoperable breast cancer is described as follows (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2A uses a blue bar to depict the temporal distribution of publications related to the applications of INPs in diagnosing and treating breast cancer.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2B provides a global overview of these studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The three clusters with the most contributions included “different electrochemical biosensors,” “cancer diagnosis,” and “accurate monitoring” (Fig. 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A timeline-based analysis was conducted to understand how these clusters were distributed across various periods (Fig. 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Keyword co-occurrence analysis revealed that the research hotspots could be divided into eight categories (Fig. 2E).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 summarizes SPIONs currently available for MRI in breast cancer.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "More importantly, compared with clinically used Gd-based small molecule contrast agents, TUG can be more engulfed by 4T1 cells, showing much enhanced T1-weighted positive MRI in both subcutaneous and orthotopic tumor models of breast cancer (the highest signal value of Magnevist = 390, whereas TUG = 430) (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the CT imaging signal of the breast tumor tissue was more than twice as strong at 3 h after injection compared with the pre-contrast image (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These characters underscore the nanohorns’ ability to persist in the tumor environment, enabling clear and detailed imaging crucial for precise tumor diagnosis (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "STBRs (signal-to-background ratios) of bMSN@T2-RGD-Acrk were nearly 2.4-fold greater than bMSN@T2-AM, suggesting that bMSN@T2-RGD-Acrk, as a targeted fluorescent nanoprobe, has significant binding and imaging capabilities for breast cancer cells, thus holding substantial value for the diagnosis and monitoring of breast cancer (Fig. 4D).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the electron microscopy results demonstrated that the nanomaterial was endocytosed by tumor, liver Kupffer cells, and spleen macrophages, indicating that it could be used for SERS imaging and removed from the body (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Although microfluidic biosensor based on INP achieved a test sensitivity of 0.01 U/mL, 0.01 U/mL, and 1 pg/mL, it strongly highlights the application value of this microfluidic chip in an early diagnosis of breast cancer (Fig. 4F).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In another study, Rajaee et al. reported the radiosensitizing ability of PEG-modified bismuth gadolinium oxide (BiGdO3-PEG NPs) in MCF-7 and 4T1 breast cancer cells (Fig. 5A) [135].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "For the first time, they evaluated the potential of KI NPs as a radiosensitizer to enhance radiotherapy in MCF-7 breast cancer cells (Fig. 5B) [144].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "To develop a novel photothermal conversion agent for the treatment of TNBC, Cheng et al. designed a novel microwave-triggered heat shock protein (HSP)-targeted gold nanosystem (cmHSP-AuNC) to improve the accumulation of gold nanomaterials by specifically targeting 4T1 cells (Fig. 6A) [161].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "For example, Ying et al. developed a novel biocompatible nanoparticle CuS@BSA-NB2 for HER2-positive breast cancer treatment (Fig. 6B) [178].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "HMSNs are used to deliver the PS and methylene blue to perform the PDT effect, and the BSA-FA structure increases the targeting ability of HMSNs (Fig. 6C) [201, 202].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Yuan et al. combined hyaluronic acid (HA) and glucose oxidase (GOX) with iridium oxide nanoparticles to create an in situ amplifier: IrO2–GOx@HA NPs (Fig. 6D) [205].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Sun et al. prepared AMF-responsive composite scaffolds (FA-Gel/FeNP) by using folic acid-modified gelatin and hybridized them with citrate-stable Fe3O4 NPs (Fe3O4-Citrate NPs) (Fig. 7A) [218].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Furthermore, this innovative DM-ACMSs system showed on–off drug release capability by remotely controlling AMF (Fig. 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Its ROS production rate constant was 1.96 × 10–1 min−1 (Fig. 8A), which is three- to eightfold higher than that of the previous studies, such as TiO2 nanospheres [229], Au–TiO2 nanosheets [230], or Au–TiO2 nanocomposites [231].",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The tumor was eradicated without recurrence in the 4T1 tumor-bearing mice (Fig. 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Li and colleagues constructed an HA-coated mesoporous silica-coated Fe3O4 nanoparticles (M-MSN/HA/DI)-based versatile nanoplatforms for the co-delivery of DOX and ICG into MDA-MB-231 breast cancer cells to perform T2 MR/FL/PA imaging and chemo/PTT capabilities (Fig. 9A) [235].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In another study, Xun et al. designed Fe3O4–Aushell Janus NPs coated with PEG (Fe3O4–Aushell–PEG160 NPs) to perform synergistic theranostics of MRI and PTT of breast cancer (Fig. 9B) [241].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Ma and colleagues constructed the multifunctional Fe3O4–Pd Janus NPs (Fe3O4–Pd JNPs) to synergistically facilitate magnetic and NIR hyperthermia, along with enhanced ROS production for breast cancer treatment (Fig. 9C) [244].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Based on the emergence of additional substantiation from evidence-based medicine, the current treatment protocol for inoperable breast cancer is described as follows (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2A uses a blue bar to depict the temporal distribution of publications related to the applications of INPs in diagnosing and treating breast cancer.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2B provides a global overview of these studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The three clusters with the most contributions included “different electrochemical biosensors,” “cancer diagnosis,” and “accurate monitoring” (Fig. 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A timeline-based analysis was conducted to understand how these clusters were distributed across various periods (Fig. 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Keyword co-occurrence analysis revealed that the research hotspots could be divided into eight categories (Fig. 2E).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 summarizes SPIONs currently available for MRI in breast cancer.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "More importantly, compared with clinically used Gd-based small molecule contrast agents, TUG can be more engulfed by 4T1 cells, showing much enhanced T1-weighted positive MRI in both subcutaneous and orthotopic tumor models of breast cancer (the highest signal value of Magnevist = 390, whereas TUG = 430) (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the CT imaging signal of the breast tumor tissue was more than twice as strong at 3 h after injection compared with the pre-contrast image (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These characters underscore the nanohorns’ ability to persist in the tumor environment, enabling clear and detailed imaging crucial for precise tumor diagnosis (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "STBRs (signal-to-background ratios) of bMSN@T2-RGD-Acrk were nearly 2.4-fold greater than bMSN@T2-AM, suggesting that bMSN@T2-RGD-Acrk, as a targeted fluorescent nanoprobe, has significant binding and imaging capabilities for breast cancer cells, thus holding substantial value for the diagnosis and monitoring of breast cancer (Fig. 4D).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the electron microscopy results demonstrated that the nanomaterial was endocytosed by tumor, liver Kupffer cells, and spleen macrophages, indicating that it could be used for SERS imaging and removed from the body (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Although microfluidic biosensor based on INP achieved a test sensitivity of 0.01 U/mL, 0.01 U/mL, and 1 pg/mL, it strongly highlights the application value of this microfluidic chip in an early diagnosis of breast cancer (Fig. 4F).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In another study, Rajaee et al. reported the radiosensitizing ability of PEG-modified bismuth gadolinium oxide (BiGdO3-PEG NPs) in MCF-7 and 4T1 breast cancer cells (Fig. 5A) [135].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "For the first time, they evaluated the potential of KI NPs as a radiosensitizer to enhance radiotherapy in MCF-7 breast cancer cells (Fig. 5B) [144].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "To develop a novel photothermal conversion agent for the treatment of TNBC, Cheng et al. designed a novel microwave-triggered heat shock protein (HSP)-targeted gold nanosystem (cmHSP-AuNC) to improve the accumulation of gold nanomaterials by specifically targeting 4T1 cells (Fig. 6A) [161].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "For example, Ying et al. developed a novel biocompatible nanoparticle CuS@BSA-NB2 for HER2-positive breast cancer treatment (Fig. 6B) [178].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "HMSNs are used to deliver the PS and methylene blue to perform the PDT effect, and the BSA-FA structure increases the targeting ability of HMSNs (Fig. 6C) [201, 202].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Yuan et al. combined hyaluronic acid (HA) and glucose oxidase (GOX) with iridium oxide nanoparticles to create an in situ amplifier: IrO2–GOx@HA NPs (Fig. 6D) [205].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Sun et al. prepared AMF-responsive composite scaffolds (FA-Gel/FeNP) by using folic acid-modified gelatin and hybridized them with citrate-stable Fe3O4 NPs (Fe3O4-Citrate NPs) (Fig. 7A) [218].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Furthermore, this innovative DM-ACMSs system showed on–off drug release capability by remotely controlling AMF (Fig. 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Its ROS production rate constant was 1.96 × 10–1 min−1 (Fig. 8A), which is three- to eightfold higher than that of the previous studies, such as TiO2 nanospheres [229], Au–TiO2 nanosheets [230], or Au–TiO2 nanocomposites [231].",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The tumor was eradicated without recurrence in the 4T1 tumor-bearing mice (Fig. 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Li and colleagues constructed an HA-coated mesoporous silica-coated Fe3O4 nanoparticles (M-MSN/HA/DI)-based versatile nanoplatforms for the co-delivery of DOX and ICG into MDA-MB-231 breast cancer cells to perform T2 MR/FL/PA imaging and chemo/PTT capabilities (Fig. 9A) [235].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In another study, Xun et al. designed Fe3O4–Aushell Janus NPs coated with PEG (Fe3O4–Aushell–PEG160 NPs) to perform synergistic theranostics of MRI and PTT of breast cancer (Fig. 9B) [241].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Ma and colleagues constructed the multifunctional Fe3O4–Pd Janus NPs (Fe3O4–Pd JNPs) to synergistically facilitate magnetic and NIR hyperthermia, along with enhanced ROS production for breast cancer treatment (Fig. 9C) [244].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Based on the emergence of additional substantiation from evidence-based medicine, the current treatment protocol for inoperable breast cancer is described as follows (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Based on the emergence of additional substantiation from evidence-based medicine, the current treatment protocol for inoperable breast cancer is described as follows (Fig. 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Figure 2A uses a blue bar to depict the temporal distribution of publications related to the applications of INPs in diagnosing and treating breast cancer.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2B provides a global overview of these studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The three clusters with the most contributions included “different electrochemical biosensors,” “cancer diagnosis,” and “accurate monitoring” (Fig. 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A timeline-based analysis was conducted to understand how these clusters were distributed across various periods (Fig. 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Keyword co-occurrence analysis revealed that the research hotspots could be divided into eight categories (Fig. 2E).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2A uses a blue bar to depict the temporal distribution of publications related to the applications of INPs in diagnosing and treating breast cancer.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2B provides a global overview of these studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The three clusters with the most contributions included “different electrochemical biosensors,” “cancer diagnosis,” and “accurate monitoring” (Fig. 2C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "A timeline-based analysis was conducted to understand how these clusters were distributed across various periods (Fig. 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Keyword co-occurrence analysis revealed that the research hotspots could be divided into eight categories (Fig. 2E).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 summarizes SPIONs currently available for MRI in breast cancer.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "More importantly, compared with clinically used Gd-based small molecule contrast agents, TUG can be more engulfed by 4T1 cells, showing much enhanced T1-weighted positive MRI in both subcutaneous and orthotopic tumor models of breast cancer (the highest signal value of Magnevist = 390, whereas TUG = 430) (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the CT imaging signal of the breast tumor tissue was more than twice as strong at 3 h after injection compared with the pre-contrast image (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These characters underscore the nanohorns’ ability to persist in the tumor environment, enabling clear and detailed imaging crucial for precise tumor diagnosis (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "STBRs (signal-to-background ratios) of bMSN@T2-RGD-Acrk were nearly 2.4-fold greater than bMSN@T2-AM, suggesting that bMSN@T2-RGD-Acrk, as a targeted fluorescent nanoprobe, has significant binding and imaging capabilities for breast cancer cells, thus holding substantial value for the diagnosis and monitoring of breast cancer (Fig. 4D).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the electron microscopy results demonstrated that the nanomaterial was endocytosed by tumor, liver Kupffer cells, and spleen macrophages, indicating that it could be used for SERS imaging and removed from the body (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Although microfluidic biosensor based on INP achieved a test sensitivity of 0.01 U/mL, 0.01 U/mL, and 1 pg/mL, it strongly highlights the application value of this microfluidic chip in an early diagnosis of breast cancer (Fig. 4F).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Figure 3 summarizes SPIONs currently available for MRI in breast cancer.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "More importantly, compared with clinically used Gd-based small molecule contrast agents, TUG can be more engulfed by 4T1 cells, showing much enhanced T1-weighted positive MRI in both subcutaneous and orthotopic tumor models of breast cancer (the highest signal value of Magnevist = 390, whereas TUG = 430) (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Figure 3 summarizes SPIONs currently available for MRI in breast cancer.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "More importantly, compared with clinically used Gd-based small molecule contrast agents, TUG can be more engulfed by 4T1 cells, showing much enhanced T1-weighted positive MRI in both subcutaneous and orthotopic tumor models of breast cancer (the highest signal value of Magnevist = 390, whereas TUG = 430) (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the CT imaging signal of the breast tumor tissue was more than twice as strong at 3 h after injection compared with the pre-contrast image (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the CT imaging signal of the breast tumor tissue was more than twice as strong at 3 h after injection compared with the pre-contrast image (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These characters underscore the nanohorns’ ability to persist in the tumor environment, enabling clear and detailed imaging crucial for precise tumor diagnosis (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These characters underscore the nanohorns’ ability to persist in the tumor environment, enabling clear and detailed imaging crucial for precise tumor diagnosis (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "STBRs (signal-to-background ratios) of bMSN@T2-RGD-Acrk were nearly 2.4-fold greater than bMSN@T2-AM, suggesting that bMSN@T2-RGD-Acrk, as a targeted fluorescent nanoprobe, has significant binding and imaging capabilities for breast cancer cells, thus holding substantial value for the diagnosis and monitoring of breast cancer (Fig. 4D).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "STBRs (signal-to-background ratios) of bMSN@T2-RGD-Acrk were nearly 2.4-fold greater than bMSN@T2-AM, suggesting that bMSN@T2-RGD-Acrk, as a targeted fluorescent nanoprobe, has significant binding and imaging capabilities for breast cancer cells, thus holding substantial value for the diagnosis and monitoring of breast cancer (Fig. 4D).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the electron microscopy results demonstrated that the nanomaterial was endocytosed by tumor, liver Kupffer cells, and spleen macrophages, indicating that it could be used for SERS imaging and removed from the body (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, the electron microscopy results demonstrated that the nanomaterial was endocytosed by tumor, liver Kupffer cells, and spleen macrophages, indicating that it could be used for SERS imaging and removed from the body (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Although microfluidic biosensor based on INP achieved a test sensitivity of 0.01 U/mL, 0.01 U/mL, and 1 pg/mL, it strongly highlights the application value of this microfluidic chip in an early diagnosis of breast cancer (Fig. 4F).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Although microfluidic biosensor based on INP achieved a test sensitivity of 0.01 U/mL, 0.01 U/mL, and 1 pg/mL, it strongly highlights the application value of this microfluidic chip in an early diagnosis of breast cancer (Fig. 4F).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In another study, Rajaee et al. reported the radiosensitizing ability of PEG-modified bismuth gadolinium oxide (BiGdO3-PEG NPs) in MCF-7 and 4T1 breast cancer cells (Fig. 5A) [135].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "For the first time, they evaluated the potential of KI NPs as a radiosensitizer to enhance radiotherapy in MCF-7 breast cancer cells (Fig. 5B) [144].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "To develop a novel photothermal conversion agent for the treatment of TNBC, Cheng et al. designed a novel microwave-triggered heat shock protein (HSP)-targeted gold nanosystem (cmHSP-AuNC) to improve the accumulation of gold nanomaterials by specifically targeting 4T1 cells (Fig. 6A) [161].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "For example, Ying et al. developed a novel biocompatible nanoparticle CuS@BSA-NB2 for HER2-positive breast cancer treatment (Fig. 6B) [178].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "HMSNs are used to deliver the PS and methylene blue to perform the PDT effect, and the BSA-FA structure increases the targeting ability of HMSNs (Fig. 6C) [201, 202].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Yuan et al. combined hyaluronic acid (HA) and glucose oxidase (GOX) with iridium oxide nanoparticles to create an in situ amplifier: IrO2–GOx@HA NPs (Fig. 6D) [205].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Sun et al. prepared AMF-responsive composite scaffolds (FA-Gel/FeNP) by using folic acid-modified gelatin and hybridized them with citrate-stable Fe3O4 NPs (Fe3O4-Citrate NPs) (Fig. 7A) [218].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Furthermore, this innovative DM-ACMSs system showed on–off drug release capability by remotely controlling AMF (Fig. 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Its ROS production rate constant was 1.96 × 10–1 min−1 (Fig. 8A), which is three- to eightfold higher than that of the previous studies, such as TiO2 nanospheres [229], Au–TiO2 nanosheets [230], or Au–TiO2 nanocomposites [231].",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The tumor was eradicated without recurrence in the 4T1 tumor-bearing mice (Fig. 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "In another study, Rajaee et al. reported the radiosensitizing ability of PEG-modified bismuth gadolinium oxide (BiGdO3-PEG NPs) in MCF-7 and 4T1 breast cancer cells (Fig. 5A) [135].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "For the first time, they evaluated the potential of KI NPs as a radiosensitizer to enhance radiotherapy in MCF-7 breast cancer cells (Fig. 5B) [144].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In another study, Rajaee et al. reported the radiosensitizing ability of PEG-modified bismuth gadolinium oxide (BiGdO3-PEG NPs) in MCF-7 and 4T1 breast cancer cells (Fig. 5A) [135].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "For the first time, they evaluated the potential of KI NPs as a radiosensitizer to enhance radiotherapy in MCF-7 breast cancer cells (Fig. 5B) [144].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "To develop a novel photothermal conversion agent for the treatment of TNBC, Cheng et al. designed a novel microwave-triggered heat shock protein (HSP)-targeted gold nanosystem (cmHSP-AuNC) to improve the accumulation of gold nanomaterials by specifically targeting 4T1 cells (Fig. 6A) [161].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "For example, Ying et al. developed a novel biocompatible nanoparticle CuS@BSA-NB2 for HER2-positive breast cancer treatment (Fig. 6B) [178].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "HMSNs are used to deliver the PS and methylene blue to perform the PDT effect, and the BSA-FA structure increases the targeting ability of HMSNs (Fig. 6C) [201, 202].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Yuan et al. combined hyaluronic acid (HA) and glucose oxidase (GOX) with iridium oxide nanoparticles to create an in situ amplifier: IrO2–GOx@HA NPs (Fig. 6D) [205].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "To develop a novel photothermal conversion agent for the treatment of TNBC, Cheng et al. designed a novel microwave-triggered heat shock protein (HSP)-targeted gold nanosystem (cmHSP-AuNC) to improve the accumulation of gold nanomaterials by specifically targeting 4T1 cells (Fig. 6A) [161].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "For example, Ying et al. developed a novel biocompatible nanoparticle CuS@BSA-NB2 for HER2-positive breast cancer treatment (Fig. 6B) [178].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "To develop a novel photothermal conversion agent for the treatment of TNBC, Cheng et al. designed a novel microwave-triggered heat shock protein (HSP)-targeted gold nanosystem (cmHSP-AuNC) to improve the accumulation of gold nanomaterials by specifically targeting 4T1 cells (Fig. 6A) [161].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "For example, Ying et al. developed a novel biocompatible nanoparticle CuS@BSA-NB2 for HER2-positive breast cancer treatment (Fig. 6B) [178].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel B",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "HMSNs are used to deliver the PS and methylene blue to perform the PDT effect, and the BSA-FA structure increases the targeting ability of HMSNs (Fig. 6C) [201, 202].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Yuan et al. combined hyaluronic acid (HA) and glucose oxidase (GOX) with iridium oxide nanoparticles to create an in situ amplifier: IrO2–GOx@HA NPs (Fig. 6D) [205].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "HMSNs are used to deliver the PS and methylene blue to perform the PDT effect, and the BSA-FA structure increases the targeting ability of HMSNs (Fig. 6C) [201, 202].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel C",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Yuan et al. combined hyaluronic acid (HA) and glucose oxidase (GOX) with iridium oxide nanoparticles to create an in situ amplifier: IrO2–GOx@HA NPs (Fig. 6D) [205].",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Sun et al. prepared AMF-responsive composite scaffolds (FA-Gel/FeNP) by using folic acid-modified gelatin and hybridized them with citrate-stable Fe3O4 NPs (Fe3O4-Citrate NPs) (Fig. 7A) [218].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Furthermore, this innovative DM-ACMSs system showed on–off drug release capability by remotely controlling AMF (Fig. 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Sun et al. prepared AMF-responsive composite scaffolds (FA-Gel/FeNP) by using folic acid-modified gelatin and hybridized them with citrate-stable Fe3O4 NPs (Fe3O4-Citrate NPs) (Fig. 7A) [218].",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Furthermore, this innovative DM-ACMSs system showed on–off drug release capability by remotely controlling AMF (Fig. 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Its ROS production rate constant was 1.96 × 10–1 min−1 (Fig. 8A), which is three- to eightfold higher than that of the previous studies, such as TiO2 nanospheres [229], Au–TiO2 nanosheets [230], or Au–TiO2 nanocomposites [231].",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The tumor was eradicated without recurrence in the 4T1 tumor-bearing mice (Fig. 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Its ROS production rate constant was 1.96 × 10–1 min−1 (Fig. 8A), which is three- to eightfold higher than that of the previous studies, such as TiO2 nanospheres [229], Au–TiO2 nanosheets [230], or Au–TiO2 nanocomposites [231].",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The tumor was eradicated without recurrence in the 4T1 tumor-bearing mice (Fig. 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Li and colleagues constructed an HA-coated mesoporous silica-coated Fe3O4 nanoparticles (M-MSN/HA/DI)-based versatile nanoplatforms for the co-delivery of DOX and ICG into MDA-MB-231 breast cancer cells to perform T2 MR/FL/PA imaging and chemo/PTT capabilities (Fig. 9A) [235].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In another study, Xun et al. designed Fe3O4–Aushell Janus NPs coated with PEG (Fe3O4–Aushell–PEG160 NPs) to perform synergistic theranostics of MRI and PTT of breast cancer (Fig. 9B) [241].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Ma and colleagues constructed the multifunctional Fe3O4–Pd Janus NPs (Fe3O4–Pd JNPs) to synergistically facilitate magnetic and NIR hyperthermia, along with enhanced ROS production for breast cancer treatment (Fig. 9C) [244].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Li and colleagues constructed an HA-coated mesoporous silica-coated Fe3O4 nanoparticles (M-MSN/HA/DI)-based versatile nanoplatforms for the co-delivery of DOX and ICG into MDA-MB-231 breast cancer cells to perform T2 MR/FL/PA imaging and chemo/PTT capabilities (Fig. 9A) [235].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "In another study, Xun et al. designed Fe3O4–Aushell Janus NPs coated with PEG (Fe3O4–Aushell–PEG160 NPs) to perform synergistic theranostics of MRI and PTT of breast cancer (Fig. 9B) [241].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel B",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Ma and colleagues constructed the multifunctional Fe3O4–Pd Janus NPs (Fe3O4–Pd JNPs) to synergistically facilitate magnetic and NIR hyperthermia, along with enhanced ROS production for breast cancer treatment (Fig. 9C) [244].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel C",
        "figure_key": "figure_9"
      }
    ]
  }
]